Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension-Reference-Cited by-同舟云学术

Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension

Published:2022-03-07 Issue:4 Volume:24 Page:449-456
ISSN:1524-6175
Container-title:The Journal of Clinical Hypertension
language:en
Short-container-title:J of Clinical Hypertension

Author:

Li Wanjing¹,Gong Minghui¹,Yu Qin²^ORCID,Liu Rihui³,Chen Kaiming⁴,Lv Wei⁵,Yao Fumei⁶,Xu Zhaolong⁷,Xu Yi⁸,Song Wei¹^ORCID,Jiang Yinong¹

Affiliation:

1. Department of Cardiology The First Affiliated Hospital of Dalian Medical University Dalian Liaoning China

2. Department of Cardiology The Affiliated Zhongshan Hospital of Dalian University Dalian Liaoning China

3. Department of Cardiology The Central Hospital of Liaoyang City Affiliated China Medical University Liaoyang Liaoning China

4. Department of Cardiology The Affiliated Central Hospital of Shenyang Medical College Shenyang Liaoning China

5. Department of Cardiology The Affiliated Shengjing Hospital of China Medical University Dalian Liaoning China

6. Department of Cardiology The Second People's Hospital of Dalian Dalian Liaoning China

7. Department of Cardiology The First Affiliated Hospital of Jinzhou Medical University Jinzhou Liaoning China

8. Department of Cardiology Dalian Locomotive Hospital Dalian Liaoning China

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jch.14454

Reference27 articles.

1. Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?

2. 2018 Chinese guidelines for prevention and treatment of hypertension – a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension;Liu LS;J Geriatr Cardiol,2018

3. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension

4. Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)

5. Chapter 3 Natriuretic Peptides in Vascular Physiology and Pathology

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma renin activity as a marker for predicting the antihypertensive effect of switching to sacubitril/valsartan in treated hypertensive patients: Usefulness in daily clinical practice;The Journal of Clinical Hypertension;2024-09-09

2. Clinical Benefit of Sacubitril/Valsartan for Hypertensive Patients in Daily Practice and Predictors of Its Antihypertensive Effect;Circulation Reports;2024-07-10

3. Sacubitril/valsartan reversal of left ventricular remodeling is associated with improved hemodynamics in resistant hypertension;Hellenic Journal of Cardiology;2024-04

4. Research Progress of Sacubitril/Valsartan in the Treatment of Patients with Resistant Hypertension;Advances in Clinical Medicine;2024

5. Different Home Blood Pressure Thresholds to Predict Perfect 24-Hour Ambulatory Blood Pressure Control in Treated Hypertension Based on an “All-in-One” Device;Hypertension;2023-11